Literature DB >> 33221285

Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Avni P Finn1, Maxwell Pistilli2, Vincent Tai3, Ebenezer Daniel2, Gui-Shuang Ying2, Maureen G Maguire2, Juan E Grunwald2, Daniel F Martin4, Glenn J Jaffe3, Cynthia A Toth5.   

Abstract

PURPOSE: To identify precursors of macular atrophy (MA) and of fibrotic scar (FS) in eyes treated with anti-vascular endothelial growth factor through pixel-mapping analysis of baseline optical coherence tomography (OCT).
METHODS: Design: Cross-sectional analysis.
SETTING: Multicenter clinical trial. PATIENT POPULATION: 68 eyes from the Comparison of Age-Related Macular Degeneration Treatments Trials. INTERVENTION: Treatment with anti-vascular endothelial growth factor agents. MAIN OUTCOME MEASURE: The percentage of MA or FS pixels with each OCT feature at baseline, and the odds ratio for baseline pixels with an OCT feature to develop MA or FS.
RESULTS: Retinal pigment epithelium atrophy and photoreceptor loss on OCT were highly predictive of MA at that location at years 2 and 5 (P < .0001), but accounted for only 22.5% of the ensuing atrophy at year 2 and less at year 5. Among pixels of MA at year 2, 78% were preceded by thick drusen, 54% by subretinal macular neovascularization (MNV), and 22.5% by no detectable OCT features. MNV, subretinal hyperreflective material, pigment epithelial detachment, intraretinal fluid, and sub-retinal pigment epithelium fluid were predictive of FS at that location (P values <.05). More than 75% of the pixels of FS at years 2 and 5 were preceded by pixels of baseline MNV.
CONCLUSIONS: Most pixels of FS were preceded by components of neovascularization. Although one-quarter of MA was accounted for by pre-existing evidence of atrophy on OCT alone, the development of MA in areas of thick drusen, areas with and without subretinal MNV lesion, and areas without detectable OCT precursors argues that the development of MA is multifactorial and may follow, in part, a non-neovascular pathway.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33221285      PMCID: PMC7979472          DOI: 10.1016/j.ajo.2020.11.002

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  34 in total

1.  Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Authors:  Ebenezer Daniel; Wei Pan; Gui-Shuang Ying; Benjamin J Kim; Juan E Grunwald; Frederick L Ferris; Glenn J Jaffe; Cynthia A Toth; Daniel F Martin; Stuart L Fine; Maureen G Maguire
Journal:  Ophthalmology       Date:  2018-02-14       Impact factor: 12.079

2.  Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.

Authors:  Sumit Sharma; Cynthia A Toth; Ebenezer Daniel; Juan E Grunwald; Maureen G Maguire; Gui-Shuang Ying; Jiayan Huang; Daniel F Martin; Glenn J Jaffe
Journal:  Ophthalmology       Date:  2016-01-09       Impact factor: 12.079

3.  Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials.

Authors:  Francis Char DeCroos; Cynthia A Toth; Sandra S Stinnett; Cynthia S Heydary; Russell Burns; Glenn J Jaffe
Journal:  Ophthalmology       Date:  2012-08-28       Impact factor: 12.079

4.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Authors:  Daniel F Martin; Maureen G Maguire; Stuart L Fine; Gui-shuang Ying; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Maryann Redford; Frederick L Ferris
Journal:  Ophthalmology       Date:  2012-05-01       Impact factor: 12.079

5.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

6.  Type 1 Choroidal Neovascularization Is Associated with Reduced Localized Progression of Atrophy in Age-Related Macular Degeneration.

Authors:  Maximilian Pfau; Philipp T Möller; Sandrine H Künzel; Leon von der Emde; Moritz Lindner; Sarah Thiele; Chantal Dysli; Jennifer Nadal; Matthias Schmid; Steffen Schmitz-Valckenberg; Frank G Holz; Monika Fleckenstein
Journal:  Ophthalmol Retina       Date:  2019-10-01

7.  Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.

Authors:  Glenn J Jaffe; Daniel F Martin; Cynthia A Toth; Ebenezer Daniel; Maureen G Maguire; Gui-Shuang Ying; Juan E Grunwald; Jiayan Huang
Journal:  Ophthalmology       Date:  2013-05-01       Impact factor: 12.079

8.  Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography.

Authors:  Sebastian M Waldstein; Wolf-Dieter Vogl; Hrvoje Bogunovic; Amir Sadeghipour; Sophie Riedl; Ursula Schmidt-Erfurth
Journal:  JAMA Ophthalmol       Date:  2020-07-01       Impact factor: 7.389

9.  Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3.

Authors:  Srinivas R Sadda; Robyn Guymer; Frank G Holz; Steffen Schmitz-Valckenberg; Christine A Curcio; Alan C Bird; Barbara A Blodi; Ferdinando Bottoni; Usha Chakravarthy; Emily Y Chew; Karl Csaky; Ronald P Danis; Monika Fleckenstein; K Bailey Freund; Juan Grunwald; Carel B Hoyng; Glenn J Jaffe; Sandra Liakopoulos; Jordi M Monés; Daniel Pauleikhoff; Philip J Rosenfeld; David Sarraf; Richard F Spaide; Ramin Tadayoni; Adnan Tufail; Sebastian Wolf; Giovanni Staurenghi
Journal:  Ophthalmology       Date:  2017-11-02       Impact factor: 12.079

10.  Recognizing Atrophy and Mixed-Type Neovascularization in Age-Related Macular Degeneration Via Clinicopathologic Correlation.

Authors:  Ling Chen; Miaoling Li; Jeffrey D Messinger; Daniela Ferrara; Christine A Curcio; K Bailey Freund
Journal:  Transl Vis Sci Technol       Date:  2020-07-07       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.